• Anixa Biosciences completed dosing the fifth cohort in its Phase 1 trial of FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
• Patients received 1×10⁷ CAR-positive cells/kg following lymphodepletion; no dose-limiting toxicities have been observed across any cohort.
• The first patient treated in the fifth cohort exhibited stable disease 90 days following treatment.
• Four patients have survived more than one year following treatment, with survival ranging from approximately 17 to 28 months.
• The sixth cohort will receive 1×10⁸ CAR-positive cells/kg following lymphodepletion, pending a routine 30-day safety review of the fifth cohort.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80294) on October 26, 2026, and is solely responsible for the information contained therein.